Library
PubMed Central Open Access
research article
Professional
Open access

gene delivery to human airway epithelia using parainfluenza virus 5 amplifying virus-like particles

Source: PubMed Central Open Access, NCBI / U.S. National Library of Medicine

Molecular Therapy. Nucleic AcidsLast synced 7/1/2026Status: syncedPMID: 42376650 pmidDOI: 10.1016/j.omtn.2026.102975

Parainfluenza virus 5 (PIV5)-derived amplifying virus-like particles (PIV5-AVLPs) are an efficient gene delivery platform with broad cell tropism. To investigate the feasibility of using PIV5-AVLPs for cystic fibrosis (CF) gene therapy, we generated AVLPs expressing enhanced green fluorescent protein (AVLP-eGFP) or a codon-optimized human cystic fibrosis transmembrane conductance regulator () coding sequence and anreporter (AVLP-CFTR). We examined the transduction efficiency and persistence of transgene expression of AVLP-eGFP in primary cultures of non-CF and CF human airway epithelia (HAE). When applied to the apical surface of HAE, the AVLP-eGFP mainly transduced ciliated epithelial cells, with lesser targeting to secretory and basal cells. Reporter transgene expression gradually diminished over a 1-month time course. Transducing approximately 15% of CF airway epithelial cells with AVLP-CFTR was sufficient to restore CFTR-dependent short-circuit current to levels similar to non-CF epithelia. Our results demonstrate that PIV5-AVLPs delivered to the apical side of HAE efficiently transduce sufficient epithelial cells to restore functional CFTR expression. PIV5-based AVLPs provide a versatile platform for the delivery of a variety of genetic cargoes to the respiratory tract. abs0010 Graphical abstract http://www.w3.org/1999/xlink float portrait ga1.jpg undfig1 anchor portrait graphical abs0015 McCray and colleagues demonstrate the ability of single-cycle parainfluenza virus 5

Abstract

Parainfluenza virus 5 (PIV5)-derived amplifying virus-like particles (PIV5-AVLPs) are an efficient gene delivery platform with broad cell tropism. To investigate the feasibility of using PIV5-AVLPs for cystic fibrosis (CF) gene therapy, we generated AVLPs expressing enhanced green fluorescent protein (AVLP-eGFP) or a codon-optimized human cystic fibrosis transmembrane conductance regulator () coding sequence and anreporter (AVLP-CFTR). We examined the transduction efficiency and persistence of transgene expression of AVLP-eGFP in primary cultures of non-CF and CF human airway epithelia (HAE). When applied to the apical surface of HAE, the AVLP-eGFP mainly transduced ciliated epithelial cells, with lesser targeting to secretory and basal cells. Reporter transgene expression gradually diminished over a 1-month time course. Transducing approximately 15% of CF airway epithelial cells with AVLP-CFTR was sufficient to restore CFTR-dependent short-circuit current to levels similar to non-CF epithelia. Our results demonstrate that PIV5-AVLPs delivered to the apical side of HAE efficiently transduce sufficient epithelial cells to restore functional CFTR expression. PIV5-based AVLPs provide a versatile platform for the delivery of a variety of genetic cargoes to the respiratory tract. abs0010 Graphical abstract http://www.w3.org/1999/xlink float portrait ga1.jpg undfig1 anchor portrait graphical abs0015 McCray and colleagues demonstrate the ability of single-cycle parainfluenza virus 5 (PIV5) vectors to deliver large nucleic acid cargoes to target cells. They generated vectors encoding a full-lengthcDNA and showed that they could correct CFTR-dependent anion transport without causing cytopathic effects in primary human airway epithelial cells. teaser abs0020

Educational only
This information is for general education and is not medical advice. Always talk to a licensed U.S. clinician about your situation, medications, or treatment decisions.